{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T07:10:51Z","timestamp":1770966651290,"version":"3.50.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.jgar.2018.01.022","type":"journal-article","created":{"date-parts":[[2018,2,5]],"date-time":"2018-02-05T07:40:40Z","timestamp":1517816440000},"page":"221-225","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections"],"prefix":"10.1016","volume":"13","author":[{"given":"Christophe","family":"Isnard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dhalluin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damasie","family":"Malandain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quentin","family":"Bruey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Auzou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jocelyn","family":"Michon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Giard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Gu\u00e9rin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Cattoir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2018.01.022_bib0005","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1128\/CMR.00111-13","article-title":"Prosthetic joint infection","volume":"27","author":"Tande","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2018.01.022_bib0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.022_bib0015","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1007\/s40265-013-0075-6","article-title":"Ceftaroline fosamil: a review of its use in the treatment of complicated skin and soft tissue infections and community-acquired pneumonia","volume":"73","author":"Frampton","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2018.01.022_bib0020","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1007\/s40265-014-0273-x","article-title":"Ceftobiprole medocaril: a review of its use in patients with hospital- or community-acquired pneumonia","volume":"74","author":"Syed","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2018.01.022_bib0025","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.cmi.2017.06.010","article-title":"New and improved? A review of novel antibiotics for Gram-positive bacteria","volume":"23","author":"Abbas","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2018.01.022_bib0030","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1093\/jac\/dkq193","article-title":"Efficacy of the new cephalosporin ceftaroline in the treatment of experimental methicillin-resistant Staphylococcus aureus acute osteomyelitis","volume":"65","author":"Jacqueline","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0035","doi-asserted-by":"crossref","first-page":"6496","DOI":"10.1128\/AAC.03600-14","article-title":"Ceftaroline-fosamil efficacy against methicillin-resistant Staphylococcus aureus in a rabbit prosthetic joint infection model","volume":"58","author":"Gatin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0040","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.diagmicrobio.2007.02.010","article-title":"In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection","volume":"58","author":"Rouse","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.022_bib0045","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.diagmicrobio.2015.10.012","article-title":"In vitro activity of ceftaroline against staphylococci from prosthetic joint infection","volume":"84","author":"Park","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.022_bib0050","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1128\/AAC.01787-10","article-title":"In vitro activity of ceftaroline against Gram-positive and Gram-negative pathogens isolated from patients in Canadian hospitals in 2009","volume":"55","author":"Karlowsky","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0055","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.medmal.2016.10.004","article-title":"In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections","volume":"47","author":"Hodille","year":"2017","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jgar.2018.01.022_bib0060","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1128\/AAC.00257-08","article-title":"Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus","volume":"52","author":"Leonard","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0065","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jgar.2016.07.010","article-title":"Methicillin-resistant Staphylococcus aureus infections: a review of the currently available treatment options","volume":"7","author":"Purrello","year":"2016","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.jgar.2018.01.022_bib0070","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/14656566.2016.1176142","article-title":"Drug treatments for prosthetic joint infections in the era of multidrug resistance","volume":"17","author":"Perez-Jorge","year":"2016","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0075","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2010.04.003","article-title":"Comparative in vitro activity of ceftobiprole against Gram-positive cocci","volume":"36","author":"Betriu","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2018.01.022_bib0080","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1128\/AAC.02465-14","article-title":"Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010","volume":"58","author":"Farrell","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0085","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1093\/jac\/dkv076","article-title":"Activity of ceftaroline and comparator agents tested against Staphylococcus aureus from patients with bloodstream infections in US medical centres (2009\u201313)","volume":"70","author":"Sader","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2018.01.022_bib0090","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.diagmicrobio.2016.01.010","article-title":"Antimicrobial activity of ceftaroline and comparator agents when tested against numerous species of coagulase-negative Staphylococcus causing infection in US hospitals","volume":"85","author":"Sader","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2018.01.022_bib0095","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1128\/AAC.05004-14","article-title":"Ceftobiprole- and ceftaroline-resistant methicillin-resistant Staphylococcus aureus","volume":"59","author":"Chan","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716518300249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T22:25:39Z","timestamp":1660429539000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716518300249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":19,"alternative-id":["S2213716518300249"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2018.01.022","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2018.01.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 International Society for Chemotherapy of Infection and Cancer. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}